Complex regional pain syndrome treatment using extracellular vesicle compositions
By administering a therapeutic MSC-secreting composition of CD63+CD9-CD81- extracellular vesicles to CRPS patients, the effectiveness of CRPS treatment was addressed, significantly reducing pain scores and improving patients' motor function and quality of life.
CN121693335APending Publication Date: 2026-03-17DIRECT BIOLOGICS LLC
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202480051939.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-09
- Filing Date
- 2024-06-07
- Publication Date
- 2026-03-17
AI Technical Summary
Technical Problem
There is a lack of safe and effective treatment modalities for complex regional pain syndrome (CRPS) in the current technology.
Method used
Treatment involves administering a therapeutic mesenchymal stem cell (MSC) secretome composition containing at least 80% extracellular vesicles of CD63+CD9-CD81- to the subject via intravenous injection.
Benefits of technology
It significantly reduces subjects' visual analog scale (VAS) pain scores, improves range of motion and muscle strength, reduces swelling and pain interference, and enhances quality of life.
✦ Generated by Eureka AI based on patent content.
Abstract
Disclosed herein are methods of treating complex regional pain syndrome in a subject by administering a therapeutic MSC secretory group product prepared by a method comprising culturing a bone marrow-derived MSC under conditions comprising an oxygen tension of less than 5% and a culture medium having a pH of less than 7.
Need to check novelty before this filing date? Find Prior Art